08 nov: Efter optur: Nordea sænker forventningerne til afkastet på aktier
08 nov: Nordea: Ingen ECB-renteforhøjelser i Draghis tid
08-11-2017 15:00:26

Zealand Pharma: Interim report for the first nine months of 2017

Relateret indhold
17 nov - 
Aktier/åbning: Genmab tager føringen efter bonus i posi..
17 nov - 
Aktier/tendens: Genmab og ISS kan komme i fokus i afdæm..
16 nov - 
Torsdagens aktier: Genmab og GN forrest i bedste dag si..
Relateret debat
09:19 - 
Jeg bragte Soliqua graf for US på banen men jeg har ogs..
24 nov - 
Ja, men hele håndfulden er nu tilstede med vanlig gener..
24 nov - 
" Hvem vinder, Rød eller Sort? " Sandheden, forhåbentli..

Company announcement - No. 50/2017

Interim report for the first nine months of 2017

Copenhagen, November 8, 2017 - Zealand Pharma A/S ("ZEAL") announces financial results and continued strong progress for its product candidates and business for the first nine months of 2017. Financial guidance for 2017 has been revised with 4-6% lower operating expenses.

Financial results for the first nine months of 2017

  • Revenue of DKK 128.5 million/USD 20.4 million[1] (DKK 54.3 million/USD 8.1 million2 in the first nine months of 2016).
  • Net operating expenses3 of DKK 251.7 million/USD 39.9 million1 (DKK 220.9 million/USD 33.1 million2 in the first nine months of 2016).
  • Net result of DKK -162.3 million/USD -25.7 million1 (DKK -206.7 million/USD -31.0 million2 in the first nine months of 2016).
  • Cash position of DKK 780.6 million/USD 123.8 million1 per September 30, 2017 (December 31, 2016: DKK 642.1 million/USD 91.0 million4, including restricted cash).

Business highlights for Q3 2017

  • Listing on the Nasdaq Global Select Market in the U.S. raising gross DKK 567 million/USD 90 million[1].

  • Initiation of Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia.

  • Orphan drug designation for dasiglucagon for the treatment of congenital hyperinsulinism was granted by FDA in the U.S.

  • Boehringer Ingelheim initiated Phase 1 trial in the amylin analog program, triggering a EUR 4 million milestone payment to Zealand.

  • Boehringer Ingelheim initiated Phase 1 trial in the GLP-1/glucagon dual agonist program.

  • Soliqua® 100/33 revenue increased 37% and payer coverage increased 4%-point over the previous quarter to cover 65% of commercial lives.

Business highlights for the period thereafter

  • Orphan drug designation for glepaglutide for the treatment of short bowel syndrome granted by FDA in the U.S.

  • The potential for less than once-daily dosing with glepaglutide is being evaluated in a clinical trial, following positive results in the Phase 2 trial for Short Bowel Syndrome.

  • Patient enrolment completed for Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia.

Britt Meelby Jensen, President and CEO of Zealand

, comments:

"We continue to see strong results and progress with our clinical product candidates, and following the U.S. IPO in August, where we raised USD 90 million, we are in a solid position to advance our late stage clinical programs at full speed. For glepaglutide, we are in preparation to start Phase 3 mid-2018, we received orphan drug designation and we are finalizing a trial to assess the potential for a better dosing option for patients. In addition, two of our partnered programs have advanced to Phase 1 for treatment of obesity and/or diabetes. With this, I am convinced that Zealand is set for a successful future."

Revised financial guidance for 2017 

For 2017, Zealand maintains its revenue guidance of a continued increase in royalty payments from Sanofi. No specific guidance on the level of royalties can be provided as Sanofi has not provided any guidance on expected 2017 sales.

Milestone revenue of DKK 101 million has been received from partners.

Net operating expenses in 2017 are expected to be within the range of DKK 375-385 million, 4-6 % lower than previously guided (DKK 390-410 million). The decrease relates to timing of clinical studies as well as tight cost control.

Operating loss before royalty income/expenses has been reduced from DKK 290-310 million to DKK 275-285 million.

Conference call today at 4 pm CET/10 am EST

Zealand's management will be hosting a conference call today at 4 pm CET/10 am EST to present the results for the first nine months of 2017. Participating in the call will be President and Chief Executive Officer Britt Meelby Jensen, Executive Vice President and Chief Financial Officer Mats Blom and Executive Vice President and Chief Medical and Development Officer Adam Steensberg. The presentation will be followed by a Q&A session.

The dial-in numbers are:

DK standard access             +45 32711658

UK and international            +44 (0) 20 3427 1907

U.S. (free dial-in)                 +1 646 254 3366

Passcode                            3321181

A live audio webcast of the call, including an accompanying slide presentation, will be available via the following link, https://edge.media-server.com/m6/p/wr84wf2d also accessible on the Investor section of Zealand's website (www.zealandpharma.com). Participants are advised to register for the webcast approximately 10 minutes before the start. A recording of the event will be made available on the Investor section of Zealand's website after the call.

For further information, please contact:

Britt Meelby Jensen, President and Chief Executive Officer

Tel.: +45 51 67 61 28, e-mail: bmj@zealandpharma.com

Mats Blom, Executive Vice President and Chief Financial Officer

Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com

[1] Translated solely for convenience into U.S. dollars at an assumed exchange rate of DKK 6.30 per USD 1.00, which was the rounded official exchange rate of such currencies at September 30, 2017.

2 Translated solely for convenience into U.S. dollars at an assumed exchange rate of DKK 6.68 per USD 1.00, which was the rounded official exchange rate of such currencies at September 30, 2016.

3 Net operating expenses consist of research, development and administrative expenses less other operating income.

4 Translated solely for convenience into U.S. dollars at an assumed exchange rate of DKK 7.05 per USD 1.00, which was the rounded official exchange rate of such currencies at December 31, 2016.

50-17_1108_ Interim Report for the first nine months


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Zealand Pharma via Globenewswire

Vedhæftet fil: 824007.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
24 nov
ZEAL
I det IPO prospekt som Zealand Pharma udsendte i sammenhæng med udstedelse af «American Depositary S..
21
18 nov
ZEAL
Den 27. oktober har Lægemiddelstyrelsen offentliggjort at det er blevet besluttet at Suliqua per 1. ..
7
20 nov
ZEAL
Her er udtalesen som var benzin på bålet da Zealand Pharma begyndt at falde. Der blev stille et spør..
6
19 nov
ZEAL
Du minder snart om GW - total kollerisk, skændes 24/7 med 90% nonsensindlæg hvor du på 5. år er "imo..
5
19 nov
ZEAL
Nej, jeg skændes ikke med nogen, blotlægger derimod ignoranters niveau, herunder dit.
5
19 nov
ZEAL
Jeg mener at Bryan Garnier seneste analyse rammer meget godt plet. Jeg tror at det er muligt at opnå..
5
24 nov
ZEAL
Prøv dog bare for en gangs skyld at kvalificere dine mange negørende postulater med bare et snert af..
4
24 nov
ZEAL
Tak for - som sædvanlig - et informativ indlæg, der afspejler en særdeles dyb viden på området. Gid ..
4
21 nov
ZEAL
Da noget pjat at skrive. Ingen kan sgu da se om det shorts eller ikke shorts. Ligner ønsketænkning.
4
24 nov
ZEAL
Selvfølgelig er patienten ikke død endnu - men den er på vej! Ligemeget hvad du kommer med af citate..
3

Mærsk-aktien får comeback og har bedste børsdag i fire måneder

24-11-2017 15:11:54
A.P. Møller-Mærsk har haft en hård periode på børsen efter selskabets regnskab tidligere på måneden, men fredag får aktien lidt tiltrængt medvind.Aktien stiger fredag eftermiddag 3,6 pct. til 10.500 kr., hvilket er den højeste stigning på én dag siden begyndelsen af juli.- Mærsk-aktien har fået rimeligt mange klø på det seneste, og så skal man også have in mente, at der er tynd volumen i markedet ..

Mærsk: Rateindeks falder til laveste i 15 måneder trods lyspunkt -NY

24-11-2017 13:35:30
SCFI-indekset over rateudviklingen på en stribe ruter fra Shanghai og ud i verden faldt igen denne uge.Indekset faldt 3,9 pct. til 705,2, viser nye data fra Shanghai Shipping Exchange, og tager dermed sit tredje dyk i træk. Indekset ligger nu på det laveste niveau siden august 2016.Ugens aflæsning er desuden 16 pct. lavere end snitniveauet hidtil i år. Raterne dykkede, selv om der var mere positiv..

Aktier/åbning: Køkkenkoncern får rolig børsdebut i uændret marked

24-11-2017 09:14:57
Køkkenkoncernen TCM Group, der blandt andet ejer brands som Svane Køkkenet og Tvis Køkkener, får fredag en noget stille debut på den københavnske fondsbørs.Resten af markedet udvikler sig også generelt roligt, og der er heller ikke større nyheder eller kommende offentliggørelser på tapetet. Det danske eliteindeks stiger knap 0,1 pct. til 1115,86 kort efter børsåbningen.Herhjemme er C20 Cap-indekse..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Genmab/Jyske: Resultatet før skat vil nærme sig 5 mia. kr. i 2019 - NY
2
C20 Cap har haft længste nedtur i tre år
3
Analytiker: Boligejere med variable lån risikerer at udhule friværdien
4
Fredagens aktier: Mærsk og FLSmidth hver sin vej i rødt C20
5
Ryanair truer ansatte - de sælger ikke nok i flyene

Relaterede aktiekurser

Zealand Pharma A/S 91,00 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
25. november 2017 10:35:42
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171124.1 - EUROWEB5 - 2017-11-25 10:35:42 - 2017-11-25 10:35:42 - 1 - Website: OKAY